Core Insights - PMGC Holdings Inc. announced a research agreement with a leading preclinical CRO to evaluate EL-32, a novel engineered probiotic, for its potential in treating obesity [1][4] - The study will assess EL-32's effects on glycemic control and body composition in diet-induced obese mice, both as a monotherapy and in combination with semaglutide [1][5] - EL-32 targets myostatin and activin-A pathways, aiming to preserve muscle mass while reducing fat mass, addressing a critical need in obesity treatment [2][4][3] Company Overview - Northstrive Biosciences Inc., a subsidiary of PMGC Holdings, focuses on developing innovative solutions for obesity treatment, particularly through engineered probiotics [7] - The lead candidate, EL-32, is designed to work alongside existing GLP-1 receptor agonists, which have been shown to cause significant muscle mass loss during weight loss [2][3][4] - PMGC Holdings operates a diversified portfolio, including Northstrive Biosciences, PMGC Research, and PMGC Capital, aiming to maximize growth across various sectors [9]
Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., Signs Agreement For Preclinical Mouse Study of EL-32, a Potential Breakthrough Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1